Upcoming clinical trials to test precision treatment for ovarian cancer
UCLA Health is conducting two clinical trials to evaluate antibody-drug conjugates (ADCs) for targeted ovarian cancer therapy, aiming to enhance treatment efficacy and reduce side effects by delivering chemotherapy directly to tumor cells.
ADCs leverage “engineered antibodies to identify specific proteins on tumor cells and deliver powerful chemotherapy directly to the cancer.” The pathway could lead to fewer side effects and improve quality of life for ovarian cancer patients. While UCLA has worked with ADCs before, they hope to uncover whether they could be useful for patients in their earlier stages of the disease.
Both trials are currently enrolling. One will combine ixotatug vedotin and pre-surgery chemotherapy in patients with tumors containing the claudin-6 protein. This trial is named CATALINA-4. The other trial will look to “an ADC that targets the folate receptor,” testing if patients could benefit from similar treatments sooner.
